Orexins A and B are two hypothalamic peptides that increase food intake and body weight and probably play a role in the sleep regulation. They act through two subtypes of G protein-coupled receptors, called OX1-R and OX2-R. OX1-R selectively binds orexin-A, whereas OX2-R is nonselective for both orexins. Orexins did not affect the in vitro secretion of either catecholamine or aldosterone from human adrenals. Conversely, orexin A, but not orexin B, concentration dependently increased basal cortisol secretion from dispersed adrenocortical cells; the maximal effective concentration was 10 Ϫ8 mol/L. Orexin A (10 Ϫ8 mol/L) enhanced the cortisol response to maximal effective concentrations (10 Ϫ9 mol/L) of angiotensin II and endothelin-1, but only to low concentrations of ACTH (10
Orexin A (10 Ϫ8 mol/L) increased basal cAMP release by dispersed adrenocortical cells, and the effect was blocked by the adenylate cyclase inhibitor SQ-22536. The cortisol response to 10 Ϫ8 mol/L orexin A was unaffected by the ACTH receptor antagonist corticotropininhibiting peptide, but was abolished by either SQ-22536 or the protein kinase A inhibitor H-89. RT-PCR demonstrated high levels of OX1-R messenger ribonucleic acid and very low levels of OX2-R messenger ribonucleic acid in human adrenal zona fasciculata-reticularis and adrenal medulla. Collectively, our findings suggest that orexins selectively stimulate glucocorticoid secretion from human adrenocortical cells, acting through OX1-R coupled with the adenylate cyclasedependent signaling pathway. M ANY LINES OF evidence indicate that close interrelationships occur between body weight homeostasis and adrenal secretory activity (1) (2) (3) (4) . Accordingly, neuropeptide Y (NPY) and leptin, two peptides that are involved in the central regulation of feeding (for review, see Refs. [5] [6] [7] , are known to control the function of the hypothalamo-pituitaryadrenal axis, acting on both central (8 -11) and peripheral (12) (13) (14) (15) branches.
Orexins A and B are two recently identified hypothalamic peptides that, like leptin and NPY, play a role in the central control of food intake (for review, see Refs. 16 -18) . They originate from the posttranslational proteolytic cleavage of a common precursor, the prepro-orexin, and act through two subtypes of G protein-coupled receptors, named OX1-R and OX2-R (16, 19) .
Recent findings indicate that orexins, through the OX2-R, may be involved in sleep regulation; their deficit provokes a narcolepsy-like condition in dogs and mice (20, 21) . Although these observations could suggest a role for orexins in the control of circadian rhythms of glucocorticoid secretion, few studies are available on the possible actions of these peptides on adrenal function. The expression of OX1-R and OX2-R messenger ribonucleic acids (mRNAs) has been recently detected in rat adrenal medulla (22) , and orexins were reported to stimulate corticosterone secretion from rat adrenals both in vivo and in vitro (23) . Hence, the present study was designed to investigate whether orexins affect in vitro adrenal function in humans by using both dispersed adrenocortical cells and adrenal slices containing adrenomedullary tissue.
Materials and Methods Reagents
All chemicals were obtained from Sigma (St. Louis, MO) with the following exceptions: orexins, corticotropin-inhibiting peptide (CIP), and endothelin-1 (ET-1) were supplied by Peninsula Laboratories, Inc. 
Incubation experiments
Adrenal glands were obtained from adult patients (40 -50 yr old) undergoing unilateral nephrectomy/adrenalectomy for kidney cancer. The criteria for patient recruitment were described previously (24) , and each patient gave written consensus. The study protocol was approved by the local ethical committee for human studies.
Portions of the head and tail of each adrenal, which are known to, respectively, contain and not contain adrenal medulla (for references, see Ref. 25) , were removed, placed in Krebs-Ringer bicarbonate buffer with 0.2% glucose at 4 C, and immediately taken to our laboratory. Head fragments were cut into slices, always including the gland capsule and medulla; tail fragments were employed to obtain dispersed adrenocortical cell preparations by sequential collagenase digestion and mechanical disaggregation (25) . Dispersed cells were actually a mixture of zona glomerulosa (ZG) aldosterone-secreting and zona fasciculata-reticularis (ZF/R) cortisol-secreting cells; the percentages of the two cell types (as evaluated by phase microscopy) were about 15% and 85%, respectively.
Dispersed adrenocortical cells and adrenal slices were placed in medium 199 and Krebs-Ringer bicarbonate buffer with 0.2% glucose containing 5 mg/mL human serum albumin. The samples were incubated (10 5 cells or 4 -5 mg/mL) as follows: 1) orexins (from 10
Ϫ8 mol/L) alone or in the presence of 10 Ϫ9 mol/L ACTH, angiotensin II (Ang-II), or ET-1; 3) ACTH (from 10
Ϫ8 mol/L) alone or in the presence of 10 Ϫ8 mol/L orexin A; and 4) CIP (10 Ϫ6 mol/L), SQ-22536 (10 Ϫ4 mol/L), and H-89 (10 Ϫ5 mol/L) alone or in the presence of 10 Ϫ8 mol/L orexin A. When cAMP production was assayed (see below), 10
Ϫ4 mol/L of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine was added to prevent cAMP metabolism. Incubation was carried out for 60 min (steroid hormone production), 30 min (catecholamine production), or 10 min (cAMP production) in a shaking bath at 37 C in an atmosphere of 95% air-5% CO 2 . At the end of the experiments, the incubation tubes were centrifuged at 4 C, and media were collected and kept frozen at Ϫ80 C.
Hormonal and cAMP assays
Aldosterone and cortisol were extracted from supernatants and purified by high performance liquid chromatography (25) ; their concentrations were measured by RIA with the following commercial kits: 1) aldosterone CTK2 (sensitivity, 5 pg/mL; intra-and interassay variations, 5.5% and 7.1%, respectively), and 2) cortisol RIA kit (sensitivity, 30 pg/mL; intra-and interassay variations, 6.7% and 8.2%, respectively).
Catecholamine concentrations were assayed, without previous allumina purification and concentration, by high performance liquid chromatography with a reverse phase column and a glassy carbon electrochemical detector, as described previously (26) . Intra-and interassay variations were 7.3% and 8.4% for norepinephrine, and 6.8% and 8.1% for epinephrine, respectively. cAMP was extracted by incubating the medium with 0.1 n HCl for 20 min at 4 C. The HCl extract was then neutralized, and the cAMP concentration was determined using the acetylation protocol of the Amersham Pharmacia Biotech Biotrak cAMP RIA system (sensitivity, 14 pg/mL; intra-and interassay variations, 5.3% and 6.6%, respectively).
RT-PCR of orexin receptors
Head fragments of two adrenals were cut into slices of about 5 mm. The capsule was stripped, and adherent parenchymal tissue (bona fide ZG) was scraped off. Adrenal medulla was then separated from ZF/R under the dissecting microscope.
RNA was extracted from adrenal samples, using the guanidium isothiocyanate method, and total RNA was reverse transcribed to complementary DNA (cDNA) with random hexamers (2.5 mol/L) and 50 U cloned Moloney murine leukemia virus reverse transcriptase, as previously detailed (27) . For amplification of the resulting cDNA, 10 L of the RT mixture were used. The sample volume was increased to 50 L with a solution containing 50 mmol/L KCl, 10 mmol/L Tris (pH 8.3), 2 mmol/L MgCl 2 , 0.1 mol/L of up-and downstream primers, and 1 U Taq polymerase. The primers used for human OX1-R and OX2-R mRNAs were selected according to the procedure of Sakurai et al. (16) : OX1-R, 5Ј-CCT TCC TGG CTG AAG TGA AG-3Ј and 5Ј-AGT GGG AGA AGG TGA AGC AG-3Ј; and OX2-R, 5Ј-ACA TGG CAC CAC TGT GTC TC-3Ј and 5Ј-TGG CTC GGA TCT GCT TTA TT-3Ј. In a Delphi 100 Thermal Cycler (Oracle Biosystem, MJ Research, Inc., Waterston, MA), we used a denaturation step at 95 C for 1 min, an annealing step at 59 C for 1 min, and an extension step at 72 C for 1 min for a total of 38 cycles. An additional extension step at 72 C for 7 min was then carried out. The sizes of the amplification products were: OX1-R, 189 bp; and OX2-R, 201 bp. Detection of the PCR amplification products was carried out by size fractionation on 2% agarose gel electrophoresis.
Statistics
Each incubation experiment was performed in triplicate or quadruplicate (three or four adrenals from three or four patients), and results were expressed as the mean Ϯ sem. They statistical comparison was performed using ANOVA, followed by the multiple range test of Duncan.
Results
Orexins did not affect basal catecholamine release from adrenal slices and aldosterone production from dispersed adrenocortical cells (Fig. 1) . Conversely, orexin A, but not orexin B, concentration dependently increased basal cortisol secretion from dispersed cells. Minimal and maximal effective concentrations were 10 Ϫ10 and 10 Ϫ8 mol/L and elicited about 1.5-and 2.4-fold increases, respectively (Fig. 2) .
Orexin A (10 Ϫ8 mol/L) did not enhance the cortisol response of dispersed adrenocortical cells to a maximal effective concentration (10 Ϫ9 mol/L) of ACTH, but increased the response to maximal effective concentrations (10 Ϫ9 mol/L) of both Ang-II and ET-1 (Fig. 3) by about 60% and 45%, respectively. However, it enhanced the cortisol response to submaximal concentrations of ACTH (10 Ϫ12 and 10 Ϫ11 mol/L) by about 55-60% (Fig. 4) . Orexin A (10 Ϫ8 mol/L) markedly stimulated basal cAMP release by dispersed adrenocortical cells (ϳ5.5-fold rise), and the effect was annulled by 10 Ϫ4 mol/L SQ-22536 (Fig. 5) . The cortisol response to 10 Ϫ8 mol/L orexin A was unaffected by 
10
Ϫ6 mol/L CIP, but was abolished by either 10 Ϫ4 mol/L SQ-22536 or 10 Ϫ5 mol/L H-89 (Fig. 6 ). RT-PCR demonstrated the presence of high levels of OX1-R mRNA and very low levels of OX2-R mRNA in both ZF/R and adrenal medulla. ZG displayed a weak expression of the OX1-R gene, and no expression of the OX2-R gene (Fig. 7) .
Discussion
Our findings provide evidence that orexin A, but not orexin B, selectively stimulates glucocorticoid secretion from dispersed human adrenocortical cells. As OX1-R selectively binds orexin A, and OX2-R is a nonselective receptor for both orexins (16, 19) , our data suggest that the cortisol secretagogue effect of orexin A involves the activation of OX1-R located on ZF/R cells. The lack of effect of orexins on both aldosterone and catecholamine secretion may be explained by assuming that human ZG and medullary cells are not provided with orexin receptors. However, this contention conflicts with our RT-PCR findings showing low and high OX1-R gene expression in ZG and adrenal medulla, respectively. It may be that these receptors located on ZG and chromaffin cells mediate orexin functions other than stimulation of aldosterone and catecholamine secretion. In this connection, we want to stress that the same discrepancy occurs as far as leptin and its receptors (Ob-R) are concerned. Ob-R mRNA was found in human adrenomedullary cells, but leptin, although able to inhibit glucocorticoid production, does not affect catecholamine secretion (14) .
As expected, human ZF/R cells respond not only to ACTH, but also to Ang-II and ET-1, because they are provided with both AT1 (28) and ET-1 receptors of A and B subtypes (29) . Orexin A enhances the cortisol response to maximal effective concentrations of Ang-II and ET-1, but only to low concentrations of ACTH, thereby making it likely that orexin A and ACTH share the same mechanism of signal transduction. The possibility that orexin A binds and activates ACTH receptors is ruled out by the demonstration that the selective ACTH receptor antagonist CIP (30) , at a concentration that was previously found to abolish the secretagogue effect of ACTH (31), does not affect the stimulatory action of orexin A on human ZF/R cells. Moreover, ACTH is a powerful aldosterone secretagogue (32), but orexin A does not enhance aldosterone production by dispersed adrenocortical cells.
It is current knowledge that the signaling mechanism of ACTH mainly involves the activation of the adenylate cyclase/protein kinase A (PKA)-dependent cascade (32) , and our findings indicate that the same occurs for orexin A. In fact, 1) orexin A enhances cAMP release by dispersed human adrenocortical cells; and 2) the cortisol response to orexin A is abolished by either the adenylate cyclase inhibitor SQ-22536 (33) or the PKA-selective inhibitor H-89 (34) . Neither inhibitor per se alters basal cortisol secretion, which rules out the possibility that their effect may be due to a nonspecific toxic lesion of the steroidogenic machinery.
The physiological relevance of our findings remains to be demonstrated, also because it is not known whether orexins circulate in the periphery at a concentration sufficient to produce the adrenocortical effects herein described. However, other hypothalamic peptides (e.g. CRH and NPY) that are able to modulate steroid hormone secretion through specific receptors located on adrenocortical cells act in a paracrine manner, being synthesized in adrenal medulla (for review, see Ref. 12) . Hence, the possibility that orexins may be locally produced in the adrenal glands remains to be explored.
Leptin is an adipostatic hormone secreted by adipocytes that decreases food intake and body weight (6, 7), displays increased plasma concentrations in obesity (35) and in patients with Cushing's syndrome (36, 37) , and has been found to inhibit glucocorticoid secretion from bovine (13) and human adrenocortical cells (14) . Conversely, orexins, hypothalamic peptides that are overexpressed in fasted and hypoglycemic animals (16, 38) , increase food intake and body weight (18) and have been found to stimulate glucocorticoid secretion from rat (23) and human adrenocortical cells. Hence, our study suggests that orexins together with leptin may take part in counterregulatory mechanisms that, through the modulation of adrenal-cortex secretory activity, are involved in the maintenance of glycemia and body weight homeostasis. 
